Ongoing treatment(s)-Hormonal therapy Page 3 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

The use of circulating tumor cells in predicting survival in chemotherapy patients

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to investigate if circulating tumor cells (CTC) levels in the blood could be used to determine the outcome for metastatic castration resistant prostate cancer patients. This study concluded that CTC levels could be used to predict survival in these patients.  Some background Treatment for metastatic...

Read More

Incidence of ovarian function recovery in women over 40 with chemotherapy induced amenorrhea

Posted by on Mar 13, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated ovarian function recovery (OFR) after chemotherapy-induced amenorrhea (absence of menstruation) in women aged 40-49 after 2 years of aromatase inhibitor (AI) therapy. The study concluded that a large number of women with chemotherapy-induced amenorrhea recover ovarian function during AI therapy.  Some...

Read More

Comparing outcomes of radiation therapy and observation in patients over 80

Posted by on Jan 5, 2017 in Prostate cancer | 0 comments

In a nutshell This study examined different treatment options for elderly men with localized prostate cancer. Researchers reported that radiation therapy with or without hormone therapy was associated with a significant survival benefit when compared to observation alone. Some background Localized prostate cancer refers to cancer that is confined...

Read More

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...

Read More

Is there a benefit of radiation to lymph node metastases during hormone therapy?

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the benefit of radiation to limited sites of cancer spread (metastases) in men no longer responding to hormone therapy. Researchers reported effective local cancer control after radiation of lymph node metastases in patients no longer responding to hormone therapy.  Some background Hormone therapy is the...

Read More

Hormone therapy during or after radiation therapy increases the risk of cardiovascular events

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...

Read More

Early use of chemotherapy in metastatic prostate cancer – an overview of current evidence

Posted by on Nov 27, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined evidence for the benefits of adding chemotherapy early to hormone therapy for metastatic prostate cancer. Authors concluded that early evidence indicates a survival benefit with the addition of chemotherapy for metastatic prostate cancer. Some background Androgen deprivation therapy (ADT) is a type of hormone...

Read More

Secondary hormone therapy with enzalutamide also effective for metastatic prostate cancer affecting the lung or liver

Posted by on Oct 9, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effects of enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the lungs and/or liver. Researchers reported that enzalutamide is safe and effective for men with mCRPC affecting the lung or liver. Some background When prostate cancer spreads outside of...

Read More